Living with Symptoms: Supportive Care and Safety
At a Glance
Supportive care is a core part of membranous nephropathy treatment: a low-sodium diet, prescribed ACE inhibitors or ARBs, careful diuretic use, daily weight checks, and evaluation for blood thinners and statins can reduce complications and help protect kidney health.
While much of the focus in membranous nephropathy (MN) is on the underlying immune attack, managing your daily symptoms is just as critical. This is called Supportive Care. It is not “optional”—it is a foundational part of treatment for every patient, designed to protect your kidneys from further damage and keep you safe from complications like blood clots [1][2].
The Daily Experience of Nephrotic Syndrome
The “leaky filter” in your kidneys causes a cluster of symptoms known as nephrotic syndrome. You may experience these on a daily basis:
- Severe Edema (Swelling): This is often the most visible symptom. Fluid leaks out of your blood vessels and pools in your tissues, usually in the legs and ankles, but it can also cause puffiness around the eyes or weight gain [3][4].
- Foamy Urine: When large amounts of protein leak into the urine, it creates a soapy or “frothy” appearance in the toilet [5]. Note: Foam can happen for other reasons. Rely on laboratory tests like the Urine Protein-to-Creatinine Ratio (UPCR) to guide your treatment rather than visual foaminess.
- Fatigue: Losing protein is physically exhausting. Many patients report a deep, persistent tiredness that doesn’t go away with rest, which may also reflect anemia or kidney dysfunction [6].
- High Cholesterol (Hyperlipidemia): When your blood protein (albumin) levels drop, your liver tries to compensate by working overtime. While it tries to make more protein, it accidentally makes more cholesterol and triglycerides as well [7][8].
Why You Need “Kidney-Protective” Medications
Even if you are not yet taking strong immune-suppressing drugs, your doctor will likely prescribe ACE Inhibitors (like lisinopril) or ARBs (like losartan).
These are not just for high blood pressure. In the kidney, they work by relaxing the “exit” blood vessel of the filter. This lowers the pressure inside the filter itself, which physically reduces the amount of protein that “squeezes” through the damaged holes [1][2]. Reducing this protein leak is one of the best ways to slow down the progression of the disease [9]. Safety check: These medications require monitoring of your potassium and creatinine levels, and they must be stopped before pregnancy.
The Danger of Blood Clots (VTE)
One of the most dangerous aspects of MN is thromboembolism—the formation of blood clots in the veins. This happens because the same “leaky filters” that lose albumin also lose natural proteins that stop your blood from clotting [10][11].
The risk is highest when your serum albumin (blood protein) level is very low.
- The Threshold: Doctors become particularly concerned when albumin drops below 2.5 g/dL (or 25 g/L). At levels below 2.0 g/dL, the risk of a clot increases significantly [12][13].
- Prophylaxis: Your doctor may evaluate you for blood thinners (anticoagulants) like warfarin or heparin to prevent clots before they happen. This decision is a careful balance: they must weigh your risk of a clot against your risk of a serious bleed, and treatment is individualized [14][15]. Never start or stop a blood thinner without your clinician.
Managing Fluid: Salt and Diuretics
To manage the swelling, you will likely take diuretics (water pills). However, these drugs often fail if you consume too much salt.
Sodium acts like a sponge, holding fluid in your body. If your salt intake is high, it can “overpower” the diuretic, making it ineffective [16]. A strict low-sodium diet (usually less than 2,000mg per day) is essential to help the medication pull fluid out of your tissues and into your urine [17]. Monitoring your weight daily is the best way to see if your fluid management is working. Do not adjust your diuretic dose independently, as aggressive diuresis can injure the kidneys, and ask your doctor about avoiding NSAIDs and preventing dehydration.
Cholesterol Management
Because the liver produces extra cholesterol during nephrotic syndrome, many MN patients are evaluated for statins. These drugs help lower the risk of heart disease depending on your overall cardiovascular risk and clinical situation. While your cholesterol may return to normal once your MN is in remission, taking a statin provides an important layer of protection during the active phase of the disease [8].
Common questions in this guide
What symptoms can membranous nephropathy cause day to day?
How do ACE inhibitors and ARBs help protect the kidneys?
What is the safest way to control swelling from nephrotic syndrome?
When is the risk of blood clots high in membranous nephropathy?
Why might someone with membranous nephropathy need a statin?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on membranous glomerulonephritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current serum albumin level, and which laboratory method was used to measure it?
- 2.Based on my albumin and protein levels, what is my estimated risk of a blood clot versus my risk of a serious bleed?
- 3.How long should I be on a stable dose of an ACE inhibitor or ARB before we decide if it is working well enough?
- 4.What is my daily sodium limit, and how will we know if my diuretics need to be adjusted?
- 5.Should I be on a statin for my high cholesterol, even if my cholesterol was normal before this diagnosis?
References
References (17)
- 1
Primary Membranous Nephropathy.
Couser WG
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(6)):983-997 doi:10.2215/CJN.11761116.
PMID: 28550082 - 2
Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment.
Lai WL, Yeh TH, Chen PM, et al.
Journal of the Formosan Medical Association = Taiwan yi zhi 2015; (114(2)):102-11.
PMID: 25558821 - 3
NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor.
Boulangé CL, Rood IM, Posma JM, et al.
Molecular omics 2019; (15(1)):39-49 doi:10.1039/c8mo00190a.
PMID: 30672550 - 4
Large B-cell Lymphoma-Associated Membranous Nephropathy With Positive PLA2R on Kidney Biopsy.
Al-Khazraji M, Al-Mufti IA, Al-Khazraji Y
Cureus 2023; (15(11)):e48902 doi:10.7759/cureus.48902.
PMID: 38106713 - 5
Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
Basnayake BMDB, Wazil AWM, Kannangara T, et al.
Journal of medical case reports 2017; (11(1)):135 doi:10.1186/s13256-017-1294-3.
PMID: 28501028 - 6
Syphilis and nephrotic syndrome: A case report and literature review.
Shibutani K, Ishikawa K, Kawai F, Mori N
IDCases 2024; (37()):e02016 doi:10.1016/j.idcr.2024.e02016.
PMID: 39040876 - 7
Nephrotic Syndrome Complications - New and Old. Part 1.
Busuioc RM, Mircescu G
Maedica 2022; (17(1)):153-168 doi:10.26574/maedica.2022.17.1.153.
PMID: 35733752 - 8
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE
Nature reviews. Nephrology 2018; (14(1)):57-70 doi:10.1038/nrneph.2017.155.
PMID: 29176657 - 9
Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan.
Yamaguchi M, Ando M, Katsuno T, et al.
Renal failure 2018; (40(1)):435-441 doi:10.1080/0886022X.2018.1487864.
PMID: 30052488 - 10
Nephrotic syndrome-induced thromboembolism in adults.
Al-Azzawi HF, Obi OC, Safi J, Song M
International journal of critical illness and injury science 2016; (6(2)):85-8 doi:10.4103/2229-5151.183019.
PMID: 27308257 - 11
Nephrotic syndrome: pathophysiology and consequences.
Ponticelli C, Moroni G
Journal of nephrology 2023; (36(8)):2179-2190 doi:10.1007/s40620-023-01697-7.
PMID: 37466816 - 12
Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.
Reynolds ML, Nachman PH, Mooberry MJ, et al.
Journal of nephrology 2019; (32(4)):669-672 doi:10.1007/s40620-018-0552-9.
PMID: 30421320 - 13
Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome-A retrospective observational study.
Welander F, Holmberg H, Dimény E, et al.
PloS one 2021; (16(7)):e0255009 doi:10.1371/journal.pone.0255009.
PMID: 34319998 - 14
Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?
Li X, Xie X, Zhao Y, et al.
Nephron 2023; (147(3-4)):193-198 doi:10.1159/000525913.
PMID: 35901785 - 15
Thromboembolism in nephrotic syndrome: controversies and uncertainties.
Parker K, Ragy O, Hamilton P, et al.
Research and practice in thrombosis and haemostasis 2023; (7(6)):102162 doi:10.1016/j.rpth.2023.102162.
PMID: 37680313 - 16
Diagnosis and Management of Nephrotic Syndrome in Adults.
Kodner C
American family physician 2016; (93(6)):479-85.
PMID: 26977832 - 17
Cardiovascular disease and risk management in patients with nephrotic syndrome.
Untersulzner C, Gauckler P, Matyjek A, et al.
Kidney research and clinical practice 2026; (45(4)):467-478 doi:10.23876/j.krcp.25.177.
PMID: 42298988
This page explains supportive care and safety issues in membranous nephropathy for informational purposes only and does not constitute medical advice. Your nephrology team should interpret your laboratory results and guide medicines, sodium limits, and blood-clot prevention.